CD274 and non-small cell lung carcinoma: Because the KEYNOTE 024 trial was built on the success of pembrolizumab monotherapy in patients with NSCLC who have high (50%≤) PD‐L1 expression,15 patients with high PD‐L1 expression tended to receive pembrolizumab in our study.